Our Services
Medical Information
Helpful Resources
Published on: 9/22/2026
Losartan potassium is an angiotensin II receptor blocker (ARB) used to lower high blood pressure, protect kidney function in people with type 2 diabetes and kidney disease, and reduce stroke risk in patients with an enlarged left heart ventricle. Common side effects include dizziness or lightheadedness when standing up, fatigue, nasal congestion, back pain, low blood pressure, and higher potassium levels in the blood, while rarer but serious reactions include swelling of the face, lips, or throat, fainting, and changes in kidney or liver function. Important details also apply to dosing, interactions with NSAIDs, potassium supplements, diuretics, and lithium, plus a serious warning against use during pregnancy. There are several factors to consider, so see below to understand the complete answer before starting, changing, or stopping this medication.
If you are dealing with dizziness, swelling, fatigue, or blood pressure symptoms and are unsure whether they are medication related or something else, a free, instant, online symptom check can help you organize what you are feeling, see which conditions may explain it, and understand when to contact your doctor or seek urgent care next.
Last reviewed for medical accuracy: 09/22/2026
Losartan potassium is a prescription medication in the class of angiotensin II receptor blockers (ARBs). It’s widely used to manage conditions related to high blood pressure and heart and kidney health. By blocking the effects of angiotensin II—a hormone that narrows blood vessels—losartan potassium helps blood vessels relax and lowers blood pressure.
Your doctor will tailor the dose based on:
Take losartan potassium at the same time each day, with or without food. If you miss a dose, take it as soon as you remember—unless it’s almost time for your next dose. Do not double up.
Most people tolerate losartan potassium well. Side effects are generally mild and often improve over time.
Losartan potassium can interact with other medications and substances. Always tell your doctor and pharmacist about everything you take.
Regular check-ups help ensure the medication is working safely and effectively.
Contact your healthcare provider right away if you experience:
If you ever feel that your symptoms could be serious or life-threatening, do not wait—seek emergency medical help immediately.
Not sure if your symptoms are related to losartan potassium or something else? Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
This information is meant to help you understand losartan potassium but does not replace professional medical advice. Talk with your doctor or pharmacist about any concerns, especially before starting or stopping any medication. If you have questions about dosage, potential interactions, or side effects, your healthcare provider is your best resource.
(References)
* Bosch X. Losartan-induced hepatotoxicity. JAMA. 1997 Nov 19;278(19):1572. PMID: 9370501.
* Johnston CI. Pharmacology of irbesartan. Expert Opin Investig Drugs. 1999 May;8(5):655-70. doi: 10.1517/13543784.8.5.655. PMID: 15992121.
* Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003. PMID: 16029066.
* Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Al-Jallal AAM. Olmesartan. Profiles Drug Subst Excip Relat Methodol. 2017;42:241-286. doi: 10.1016/bs.podrm.2017.02.005. Epub 2017 Mar 31. PMID: 28431778.
* Drugs for gout. Med Lett Drugs Ther. 2019 Mar 11;61(1567):33-37. PMID: 30845096.
* Drugs for hypertension. Med Lett Drugs Ther. 2020 May 18;62(1598):73-80. PMID: 32555118.
* Glick A, Sista V, Johnson C. Oral Manifestations of Commonly Prescribed Drugs. Am Fam Physician. 2020 Nov 15;102(10):613-621. PMID: 33179891.
* Drugs for gout. Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-175. doi: 10.58347/tml.2023.1688a. PMID: 37871110.
* Drugs for hypertension. Med Lett Drugs Ther. 2024 May 27;66(1703):81-88. doi: 10.58347/tml.2024.1703a. PMID: 38771738.
* Drzyzga Ł, Śpiewak D, Dorecka M, Wyględowska-Promieńska D. Available Therapeutic Options for Corneal Neovascularization: A Review. Int J Mol Sci. 2024 May 17;25(10). doi: 10.3390/ijms25105479. Epub 2024 May 17. PMID: 38791518; PMCID: PMC11121997.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.